Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been assigned an average rating of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $40.00.

A number of equities research analysts have recently issued reports on the company. Guggenheim reaffirmed a “buy” rating and set a $40.00 target price on shares of Aclaris Therapeutics in a research report on Tuesday, July 4th. Jefferies Group LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of Aclaris Therapeutics in a research report on Wednesday, June 28th. Cantor Fitzgerald assumed coverage on Aclaris Therapeutics in a research report on Friday, June 16th. They set an “overweight” rating and a $50.00 target price on the stock. ValuEngine raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Finally, Zacks Investment Research lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, May 12th.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. First Mercantile Trust Co. increased its position in shares of Aclaris Therapeutics by 11.2% in the first quarter. First Mercantile Trust Co. now owns 5,945 shares of the biotechnology company’s stock worth $177,000 after buying an additional 600 shares during the period. Nationwide Fund Advisors increased its position in shares of Aclaris Therapeutics by 8.3% in the first quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock worth $198,000 after buying an additional 510 shares during the period. Columbus Circle Investors increased its position in shares of Aclaris Therapeutics by 12.9% in the first quarter. Columbus Circle Investors now owns 180,320 shares of the biotechnology company’s stock worth $5,377,000 after buying an additional 20,642 shares during the period. Rice Hall James & Associates LLC increased its position in shares of Aclaris Therapeutics by 0.3% in the first quarter. Rice Hall James & Associates LLC now owns 34,827 shares of the biotechnology company’s stock worth $1,039,000 after buying an additional 93 shares during the period. Finally, Capital Impact Advisors LLC purchased a new position in shares of Aclaris Therapeutics during the first quarter worth approximately $1,031,000. Hedge funds and other institutional investors own 88.52% of the company’s stock.

Aclaris Therapeutics (ACRS) traded down 0.39% during midday trading on Monday, reaching $28.23. 143,075 shares of the company were exchanged. Aclaris Therapeutics has a 52-week low of $18.24 and a 52-week high of $33.25. The company’s market capitalization is $754.67 million. The company has a 50 day moving average of $25.28 and a 200-day moving average of $28.08.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.48) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.06. On average, equities research analysts anticipate that Aclaris Therapeutics will post ($3.22) earnings per share for the current fiscal year.

WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/07/16/brokerages-set-aclaris-therapeutics-inc-acrs-target-price-at-40-00-updated.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.